Loading...
Loading...
Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Ltd. Spoken Alpha tracks TLX's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks TLX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 70% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for TLX.
curl https://api.spokenalpha.com/v1/companies/TLX| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.56 | $3.21 | +11.0% | +2.1% | -0.7% |
| Q4 FY2026 | $3.71 | $3.38 | +9.8% | 0.0% | -1.8% |
| Q3 FY2026 | $3.92 | $3.47 | +12.9% | -2.2% | -5.1% |
| Q2 FY2026 | $4.13 | $3.51 | +17.8% | -2.7% | -3.8% |
| Q1 FY2025 | $3.58 | $3.35 | +6.8% | +1.2% | +3.5% |
| Q4 FY2025 | $4.07 | $3.46 | +17.7% | -5.2% | -7.5% |
| Q3 FY2025 | $3.98 | $3.59 | +10.9% | -4.5% | -6.2% |
| Q2 FY2025 | $4.13 | $3.54 | +16.7% | +0.5% | -2.0% |
| Q1 FY2024 | $4.10 | $3.43 | +19.6% | -4.8% | -3.1% |
| Q4 FY2024 | $3.71 | $3.51 | +5.7% | -6.6% | -9.3% |